15th Dec 2006 11:10
SR Pharma plc (the 'Company')
Total Voting Rights
London 15 December 2006 - In conformity with the Transparency Directive's transitional provision 6, the Company notifies the market of the following:
As at the date of this announcement, the Company's issued share capital consists of 113,064,951 ordinary shares with a nominal value of 1p each ('Ordinary Shares'), with voting rights. The Company does not hold any Ordinary Shares in Treasury.
Therefore, the total number of Ordinary Shares with voting rights is 113,064,951.
The above figure of 113,064,951 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.
- Ends - SR Pharma (www.srpharma.com)
SR Pharma plc is a European biopharmaceutical company, listed on AIM. The Company has two operating subsidiaries Atugen AG (www.atugen.com) based in Berlin, Germany and Stanford Rook Ltd based in London, UK.
SR Pharma is a world leader in RNAi therapeutics, which is a Nobel Prize winning technology that "silences" genes linked to the onset of disease. The Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi"), which have a number of advantages over conventional siRNA molecules including enhanced stability against nuclease degradation. In addition, the Company has developed a proprietary delivery system ("AtuPLEX"), which increases bioavailability, circulation times and functional intracellular uptake of siRNA molecules.
SR Pharma has an additional AtuRNAi compound partnered with Quark Biotech and Pfizer, which is also anticipated to enter clinical trials in the near future. SR Pharma also expects to begin the clinical development of its own AtuRNAi therapeutic molecules for systemic cancer indications in 2007.
In addition, SR Pharma owns a proprietary Mycobacterium vaccae-based technology and related products. Currently the Company is in discussions with third parties regarding the co-development and out-licensing of these products.
Forward-Looking Statements
This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward--looking statements are based on information currently available to SR Pharma and SR Pharma assumes no obligation to update any such forward-looking statements.
Enquiries:
For further information, please contact the following:
SR Pharma plc Citigate Dewe Rogerson +44(0)20 7307 1620 +44(0)20 7282 1050 Iain Ross, Chairman David Dible
Melvyn Davies, Finance Director Valerie Auffray
Yvonne Alexander Atugen AG +49(0)30 9489 2800
Thomas Christĩly, Chief Executive Officer
Dr. Klaus Giese, Chief Scientific Officer
SR PHARMA PLCRelated Shares:
SLN.L